Somatostatin receptors: From signaling to clinical practice
The DOI matches its Crossref record; 289 of the 289 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dopamine receptors: from structure to function
MISSALE, C., NASH, S. R., ROBINSON, S. W., JABER, M., & CARON, M. G. (1998) · Physiological Reviews · doi:10.1152/physrev.1998.78.1.189 · Cited by 3,633
Seger, R., & Krebs, E. G. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.9.7601337 · Cited by 3,602
Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone
Brazeau, P., Vale, W., Burgus, R., Ling, N., Butcher, M., Rivier, J., & Guillemin, R. (1973) · Science · doi:10.1126/science.179.4068.77 · Cited by 3,532
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Rinke, A., Müller, H.-H., Schade-Brittinger, C., Klose, K.-J., Barth, P., Wied, M., Mayer, C., Aminossadati, B., Pape, U.-F., Bläker, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8510 · Cited by 2,508
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019 · cited 1×
“…of this pathway is expected to improve the efficacy of somatostatin analogs. mTOR inhibitors (e.g. rapamycin, RAD001/everolimus) have potent antiproliferative properties and are indicated for tumors with overactivated PI3K/Akt pathway (Bjornsti and Houghton, 2004; Shaw and Cantley, 2006).”
Somatostatin and Its Receptor Family
Patel, Y. C. (1999) · Frontiers in Neuroendocrinology · doi:10.1006/frne.1999.0183 · Cited by 1,648
Krenning, E. P., Kwekkeboom, D. J., Bakker, W. H., Breeman, W. A. P., Kooij, P. P. M., Oei, H. Y., van Hagen, M., Postema, P. T. E., de Jong, M., Reubi, J. C., et al. (1993) · European Journal of Nuclear Medicine · doi:10.1007/bf00181765 · Cited by 1,564
Kwekkeboom, D. J., de Herder, W. W., Kam, B. L., van Eijck, C. H., van Essen, M., Kooij, P. P., Feelders, R. A., van Aken, M. O., & Krenning, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2553 · Cited by 1,456
The Pezcoller lecture: cancer cell cycles revisited.
Sherr, C. J. (2000) · PubMed · Cited by 1,408
Cited by
Trends in peptide drug discovery
Muttenthaler, M., King, G. F., Adams, D. J., & Alewood, P. F. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00135-8 · Cited by 1,964
A Consensus Statement on acromegaly therapeutic outcomes
Melmed, S., Bronstein, M. D., Chanson, P., Klibanski, A., Casanueva, F. F., Wass, J. A. H., Strasburger, C. J., Luger, A., Clemmons, D. R., & Giustina, A. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0058-5 · Cited by 561
Near-infrared (NIR) fluorescence-emitting small organic molecules for cancer imaging and therapy
Li, H., Kim, Y., Jung, H., Hyun, J. Y., & Shin, I. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00722c · Cited by 356
Nanoscale Self-Assembly for Therapeutic Delivery
Yadav, S., Sharma, A. K., & Kumar, P. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00127 · Cited by 324
Günther, T., Tulipano, G., Dournaud, P., Bousquet, C., Csaba, Z., Kreienkamp, H.-J., Lupp, A., Korbonits, M., Castaño, J. P., Wester, H.-J., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015388 · Cited by 253
Somatostatin Receptor Based Imaging and Radionuclide Therapy
Xu, C., & Zhang, H. (2015) · BioMed Research International · doi:10.1155/2015/917968 · Cited by 49
HTR6 and SSTR3 targeting to primary cilia
Barbeito, P., & Garcia-Gonzalo, F. R. (2021) · Biochemical Society Transactions · doi:10.1042/bst20191005 · Cited by 20
Metadata
- Authors
- Theodoropoulou, M., & Stalla, G. K.
- Venue
- Frontiers in Neuroendocrinology
- Publisher
- Elsevier BV
- Published
- 2013-08
- Volume
- 34
- Issue
- 3
- Pages
- 228-252
- ISSN
- 0091-3022 (ISSN-L)
- OpenAlex
- W2015321769
- Cited by
- 410
- References
- 289
- FWCI
- 15.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.